BANDIT trial

Efficacy of endoscopic submucosal resection with ligation device for small rectal neuroendocrine tumor: an open-label randomized control trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs042210124

Enrollment

266

Registered

2022-01-06

Start date

2022-01-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rectal neuroendocrine tumor

Interventions

arm A: endoscopic submucosal dissection arm B: endoscopic submucosal resection with ligation device

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with rectal neuroendocrine tumors of <=10 mm in size

Exclusion criteria

Exclusion criteria: Local recurrence after previous polypectomy attempts Inflammatory bowel disease, polyposis syndrome Hematological abnormality Active infectious disease Hemodialysis Infeasibility of suspending antithrombotic drugs Pregnant woman

Design outcomes

Primary

Measure	Time frame
En bloc resection with histologically tumor-free margins	—

Secondary

Measure	Time frame
(1) En bloc resection (2) Mean procedure time (3) Adverse events (4) Length of hospital stay (5) Cost analysis (6) Adverse events on resection defect closure (7) Outcomes between experts and non-expert endoscopists (8) Risk factors for incomplete resection	—

Contacts

Public ContactKazunori Takada

Shizuoka Cancer Center

ka.takada@scchr.jp+81-55-989-5222

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026